ONCO Share Price Performance
Recent ONCO News & Updates
No updates
Onconetix, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -110.17
- Gross Margin
- 47.37%
- Net Profit Margin
- -2,986.26%
- Debt/Equity Ratio
- 198.3%
Onconetix, Inc. Competitors
About ONCO
- Founded
- 2018
- Employees
- 5
- CEO
- WebsiteView website
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.7%
- 1 Year: 17.5%
- Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. As for the longer term, the market has actually risen by 18% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading